Participants were randomly assigned to receive either weekly injections of tirzepatide or an non-acting placebo
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on therapeutic response and tolerability
These statistics provide a strong foundation for setting realistic expectations and demonstrate that tirzepatide is a powerful tool for chronic weight management Results vary based on dose, lifestyle, and individual response
Flatulence was more common with higher doses of Ozempic, but fewer than 2% of clinical trial participants reported this side effect
Draw air into your syringe equal to the volume you plan to withdraw, about 25 units of air for a 25-unit draw, for example
However, the potential side effects of semaglutide could create symptoms similar to a UC flare, make it trickier to know whether your symptoms are related to UC, and affect your overall quality of life